Bronchiectasis Clinical Research Study for adults, currently being treated with established therapy

Study on Investigational Medication for Bronchiectasis

Recruiting
18-85 years
All
Phase 2
300 participants needed
6 Locations

Study Overview

This study is looking for individuals ages 18 to 85 with bronchiectasis who require treatment in addition to their current therapies.   Bronchiectasis is a long-lasting lung disease characterized by the enlargement of the air passages inside the lungs due to weakening of the airway vessel wall, which leads to symptoms such as shortness of breath, coughing up sputum and sometimes blood, wheezing (high pitch sound while breathing), and frequent lung infections.  

 

Available standard treatments for bronchiectasis are not always effective. The investigational medication (itepekimab) is being investigated as a possible treatment for bronchiectasis. It binds to a specific substance in the body that is crucial for the function of certain cells in our immune system.  Itepekimab is an injectable treatment and is administered under the skin (subcutaneously) via a prefilled syringe.  Injections will be given every two weeks.  

 

If you are interested in learning more about this study, we encourage you to complete a brief questionnaire to help determine if you may qualify to participate and be referred to a site recruiting in your area for further evaluation.

Study Details

This study will have about 300 participants in approximately 20 countries.   

 

All participants will receive either the investigational medication or placebo (in addition to their usual medications).   The treatment is randomly chosen for each participant.  There is a 2 in 3 chance of receiving the investigational medication.  

 

This study is a blinded study. Blinded means that neither the people taking part, nor the study doctors know who is given the investigational medicine or the placebo.

 

The total study duration will be between 44-77 weeks, depending on when you start the study.  Treatment will last at least 24 weeks and no longer than 52 weeks.  There will be 12 site visits and up to 5 phone visits.  Study tests include:

·         Physical exam

·         Vital signs

·         Medical history

·         Bronchiectasis severity index

·         Electrocardiogram (ECG)

·         Chest CT (computed tomography scan)

·         Spirometry

·         Blood and urine testing

·         Assessments / questionnaires

 

There is no cost to participate.  All study-related exams, study-related medications and study-related medical care is provided.  There is no insurance required to take part in this study.  You may be compensated for time and travel.  

 

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Respiratory tract disease, Bronchiectasis
  • Age: Between 18 Years - 85 Years
  • Gender: All

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchiectasis
  • Age: Between 18 Years - 85 Years
  • Gender: All

 

Updated on 13 Dec 2024. Study ID: NCT06280391

This study investigates bronchiectasis, a chronic lung condition where the airways become enlarged due to weakened airway walls. This can lead to symptoms like shortness of breath, coughing up mucus or blood, wheezing, and frequent lung infections. The purpose of this study is to explore the effects of an investigational medication that is given as an injection under the skin every two weeks.

Participants in this study will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. The study is designed so that neither the participants nor the doctors know who receives the investigational medication or the placebo. Study procedures include physical exams, vital sign checks, medical history reviews, and various tests such as spirometry and chest CT scans.

  • Who can participate
    - Ages 18 to 85
    - Diagnosed with bronchiectasis
    - Open to all genders
  • Study Details
    - Participants will receive either the investigational medication or a placebo.
    - Injections are given every two weeks, with a 2 in 3 chance of receiving the investigational medication
  • Study Timelines and Visits: The study will last between 44-77 weeks.The study requires 12 visits

Pre-Screener

Check if you are eligible Enter contact information Select a study center

Are you between the ages of 18-85?


Preview complete

The prescreener preview is complete. You may now close the preview.